Related Experiment Video

Updated: May 10, 2025

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

17.7K

Baloxavir Treatment to Reduce Influenza Virus Transmission

Timothy M Uyeki1,2, Vivien G Dugan1,2, Demetre C Daskalakis2

  • 1Division of Influenza, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta.

The New England Journal of Medicine
|April 23, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
09:07

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses

Published on: January 20, 2017

9.8K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K

Related Experiment Videos

Last Updated: May 10, 2025

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

17.7K
Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
09:07

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses

Published on: January 20, 2017

9.8K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K

Related Concept Videos

Viral Recombination00:57

Viral Recombination

23.1K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.1K
Viral Mutations00:36

Viral Mutations

32.0K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.0K

Articles linked to this work by shared authors, journal, and citation graph.

Risk factors for hospital admission and mortality in patients with influenza virus infection: a systematic review and meta-analysis.

The Lancet. Respiratory medicine·2026

Influenza.

Nature reviews. Disease primers·2026

Antiviral Dispensing for Influenza Outpatients Younger Than 65 Years With Comorbidities: A Retrospective Cohort Study.

Open forum infectious diseases·2026

A Centralized Text Message Recall for Pediatric Influenza Vaccination, New York City, 2017.

Journal of public health management and practice : JPHMP·2026

Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season.

JAMA network open·2026

Fatal Human Case of Highly Pathogenic Avian Influenza A(H5N5) in a Backyard Flock Owner - Washington, November 2025.

MMWR. Morbidity and mortality weekly report·2026

Treatment Decisions in Multiple Myeloma.

The New England journal of medicine·2026

Outbreak of Severe Methemoglobinemia during Maritime Migration.

The New England journal of medicine·2026

Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.

The New England journal of medicine·2026

Tozorakimab to Prevent COPD Exacerbations.

The New England journal of medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us